Going forward, the process for electronic drug submissions has changed. Should a manufacturer wish to make a formulary submission, they should email email@example.com to inform our staff of their intent.
The manufacturer will be sent a link to a secure portal that can be used to submit the documents. Once a manufacturer has submitted through this process once, all subsequent submissions can be made the same way, using the same portal link.
Oncology submissions should also be directed to the Nova Scotia Cancer Care Program at firstname.lastname@example.org
If you have any questions about the process, please contact Brenda Legault at the above-referenced e-mail address.
Assesses the clinical and cost effectiveness of drugs that do not fall under the mandates of the National Common Drug Review (CDR) or the Pan Canadian Oncology Drug Review (pCODR), and provides formulary listing recommendations to the provincially funded drug plans in Atlantic Canada.
Conducts objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs, and also provides formulary listing recommendations to Canada’s publicly funded drug plans (except Quebec).
Visit Common Drug Review (CDR) website
Determines interchangeability among pharmaceutical products and recommends to the Nova Scotia Department of Health and Wellness those products which will appear as interchangeable in the Nova Scotia Formulary.
Assesses cancer drugs and makes recommendations to the provinces and territories to guide their drug funding decisions.
Visit Pan-Canadian Oncology Drug Review (pCODR) website